by GlyTherix | Dec 15, 2023
We are excited to welcome Dr Alan Harris to our Advisory Board. Dr Harris comes with a long history of success in the radiopharmaceutical space as a researcher, commercializer and businessman (see here). The company has been guided by Alan during the first phase of...
by GlyTherix | Oct 10, 2023
Sydney, Australia – 10 Oct 2023. GlyTherix Ltd (GlyTherix), an Australian immuno-oncology company specialising in developing antibody radiopharmaceuticals for solid tumours is pleased to announce that it has entered into a Collaborative Research Agreement with the...
by GlyTherix | Jul 22, 2023
Sydney, Australia – July 22, 2023. GlyTherix Ltd (GlyTherix), an Australian immuno-oncology company specialising in developing antibody radiopharmaceuticals for solid tumours is pleased to announce a cornerstone investment by Cyclowest Holdings Pty Ltd (Cyclowest) in...
by GlyTherix | Jun 16, 2023
GlyTherix is pleased to announce that our key composition of matter patent titled “Monoclonal Anti-GPC-1 antibodies and uses thereof” has now completed in-country registration. We now have protection in 21 countries including US, UK, Europe, China, Japan, and...
by GlyTherix | Feb 21, 2023
ANSTO to supply Lutetium-177 for GlyTherix’s Phase Ib therapeutic trial in patients with prostate, pancreatic and bladder cancers Phase Ib basket clinical trial expected to start in late 2023 Sydney, Australia – February 21, 2023 – GlyTherix Ltd, an Australian...
by GlyTherix | Aug 11, 2022
We are pleased to announce that our key composition of matter patent for GlyTherix Ltd’s proprietary antibody to GPC-1 is now registered in 20 countries including US, Australia, China and Japan as well as several key European countries. The company’s IP estate is...
